 Kansas City Star |
DEALTALK-White knight could be elusive for Genzyme
Reuters BOSTON, July 30 (Reuters) – Chances are, every big pharmaceutical company is running the numbers and weighing the pros and cons of acquiring Genzyme Corp (GENZ.O). French drugmaker Sanofi-Aventis (SASY.PA) is poised to make a bid for the … Genzyme Call Options Should Be Purchased Given Takeover Battle, MKM Says Sanofi CEO targeting everything but blockbusters CORRECTED-NEWSMAKER-Sanofi's new broom CEO gets serious on M&A |
Related posts:
- DEALTALK-White knight could be elusive for Genzyme – Reuters
- Sanofi Said to Have Offered to Make a Bid for Genzyme – New York Times
- Biogen, Genzyme, Allergan Get Boost On Sanofi Deal Report – Wall Street Journal
- Genzyme says Carl Icahn to nominate 4 to its board – Reuters
- Genzyme, Icahn Reach Agreement To End Proxy Fight – Wall Street Journal
Secured by